

## PRODUCT DATA SHEET

Bioworld Technology CO., Ltd.



### SMG7 (K548) Peptide

Cat No.: BS2112P

#### Background

In humans, NMD depends on RNA-dependent ATPase and 5' to 3' helicase UPF1, plus six other proteins designated SMG1, SMG5, SMG6, SMG7, UPF2 and UPF3. SMG5, SMG7 and UPF1 localize to cytoplasmic foci called P-bodies, while SMG5, SMG6 and SMG7 target UPF1 for dephosphorylation. SMG7 may also act as an adaptor in targeting mRNAs associated with phosphorylated UPF1 for degradation. SMG7 provides a link between the NMD pathway and mRNA degradation machinery by forming a complex with the proteins SMG5 and UPF1, interacting with them via its N-terminal domain, and targeting bound reporter transcripts for decay via its C-terminal domain. SMG7 contains a 14-3-3-like domain, and residues that bind phosphoserine-containing peptides in 14-3-3 proteins are conserved at the equivalent positions in SMG7.

#### Swiss-Prot

Q92540

#### Applications

Blocking

#### Specificity

This peptide can be used with studies using BS2112 SMG7 (K548) pAb.

#### Purification & Purity

Synthetic peptide SMG7 (K548). (Note: the amino acid sequence is proprietary). The purity is > 98%.

#### Product

1 mg/ml in DI water.

#### Storage & Stability

Store at 4 °C short term. Aliquot and store at -20 °C long term. Avoid freeze-thaw cycles.

#### Research Use

For research use only, not for use in diagnostic procedure.